A Relative Cost of Control Analysis of IDegLira versus Other Forms of Basal Insulin Intensification in Mexico

Juan Carlos Garnica-Cuellar, Enrique Morales-Villegas, Carmen Alicia López-Forero (), Bárbara Monroy-Cruz, Bhrugu Pariti, Swati Deshwal, Manisha Sekharan, Mariana Osorio-Hernández and Ida Caterina García-Appendini
Additional contact information
Juan Carlos Garnica-Cuellar: Endocrinología del Centro Médico Nacional 20 de Noviembre, ISSSTE
Enrique Morales-Villegas: Centro de Investigación Cardio Metabólica
Carmen Alicia López-Forero: Novo Nordisk México
Bárbara Monroy-Cruz: Novo Nordisk México
Bhrugu Pariti: Novo Nordisk Global
Swati Deshwal: Novo Nordisk Global
Manisha Sekharan: Novo Nordisk Global
Mariana Osorio-Hernández: IQVIA Mexico
Ida Caterina García-Appendini: IQVIA Mexico

PharmacoEconomics - Open, 2023, vol. 7, issue 5, No 11, 849 pages

Abstract: Abstract Objectives Achieving glycemic control in patients with type 2 diabetes is important as it reduces the risk of complications and their related clinical and economic burden. Yet therapeutic inertia due to the fear of hypoglycemia, complex treatment regimens, weight gain, and therapy costs, among others, limits achieving glycemic control. This analysis aims to assess the short-term cost of control (cost per patient achieving treatment goals) with insulin degludec/liraglutide (IDegLira) versus other forms of basal insulin intensification (insulin glargine titration, basal-bolus therapy, and the combination of insulin glargine and lixisenatide: IGlarLixi) in type 2 diabetes patients not controlled with basal insulin in the Mexican private setting. Methods The proportion of patients achieving treatment goals was obtained from DUAL V and DUAL VII studies (full trial population) and a indirect treatment comparison analyzing IDegLira versus IGlarLixi. Annual cost of treatment was estimated using unitary costs from IQVIA’s Pharmaceutical Market Mexico (PMM) audit and wholesale acquisition costs (both from December 2021). The cost of control was estimated by dividing the annual cost of treatment by the proportion of patients achieving the corresponding treatment goal: glycated hemoglobin (HbA1C)

Date: 2023
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s41669-023-00421-2 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:pharmo:v:7:y:2023:i:5:d:10.1007_s41669-023-00421-2

Ordering information: This journal article can be ordered from
http://www.springer.com/adis/journal/41669

DOI: 10.1007/s41669-023-00421-2

Access Statistics for this article

PharmacoEconomics - Open is currently edited by Timothy Wrightson and Christopher Carswell

More articles in PharmacoEconomics - Open from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().